V. Servent

2.4k total citations · 1 hit paper
30 papers, 1.2k citations indexed

About

V. Servent is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, V. Servent has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in V. Servent's work include Breast Cancer Treatment Studies (12 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (9 papers). V. Servent is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (9 papers). V. Servent collaborates with scholars based in France, Spain and United States. V. Servent's co-authors include G. Albrand, Pierre Soubeyran, Hubert Rousselot, Carine Bellera, M. Rainfray, O. Saint Jean, Simone Mathoulin‐Pélissier, Damien Heitz, Isabelle Van Praagh and Christophe Desauw and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

V. Servent

29 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

2014 368 citations Pierre Soubeyran, Carine Bellera et al. PLoS ONE profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Servent France	12	610	352	304	300	224	30	1.2k
Daris Ferrari Italy	24	836 1.4×	585 1.7×	187 0.6×	168 0.6×	164 0.7×	69	1.7k
Catherine Fortpied Belgium	16	405 0.7×	291 0.8×	141 0.5×	162 0.5×	96 0.4×	52	1.0k
Jean-Pierre Droz France	12	795 1.3×	575 1.6×	144 0.5×	520 1.7×	340 1.5×	12	2.0k
A. Stotter United Kingdom	18	665 1.1×	428 1.2×	408 1.3×	256 0.9×	139 0.6×	37	1.4k
Camille Chakiba France	15	370 0.6×	316 0.9×	125 0.4×	167 0.6×	113 0.5×	35	798
Jean-Luc Verhaeghe France	13	303 0.5×	219 0.6×	266 0.9×	209 0.7×	143 0.6×	36	1.0k
Daan ten Bokkel Huinink Netherlands	15	468 0.8×	501 1.4×	62 0.2×	137 0.5×	267 1.2×	32	1.2k
Vanita Noronha India	16	456 0.7×	404 1.1×	120 0.4×	71 0.2×	56 0.3×	97	1.0k
Isabelle Neyroud‐Caspar Switzerland	13	724 1.2×	256 0.7×	631 2.1×	66 0.2×	37 0.2×	19	1.2k
Leigh A. Cantrell United States	21	434 0.7×	278 0.8×	139 0.5×	103 0.3×	90 0.4×	52	2.6k

Countries citing papers authored by V. Servent

Since Specialization

Citations

This map shows the geographic impact of V. Servent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Servent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Servent more than expected).

Fields of papers citing papers by V. Servent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Servent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Servent. The network helps show where V. Servent may publish in the future.

Co-authorship network of co-authors of V. Servent

This figure shows the co-authorship network connecting the top 25 collaborators of V. Servent. A scholar is included among the top collaborators of V. Servent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Servent. V. Servent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jacot, William, Paul Cottu, Frédérique Berger, et al.. (2019). Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Research. 21(1). 121–121. 56 indexed citations

Dansin, Éric, V. Servent, Y Robin, et al.. (2015). EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report. Case Reports in Oncology. 8(1). 164–168. 7 indexed citations

Soubeyran, Pierre, Carine Bellera, Damien Heitz, et al.. (2014). Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study. PLoS ONE. 9(12). e115060–e115060. 368 indexed citations breakdown →

Mailliez, Audrey, V. Servent, Jacques Bonneterre, & Émilie Le Rhun. (2014). Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine. Case Reports in Oncology. 7(2). 555–559.

Nabholtz, J.-M., Marie‐Ange Mouret‐Reynier, V. Servent, et al.. (2013). Cetuximab in combination with docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicentre neoadjuvant pilot phase II study.. Journal of Clinical Oncology. 31(15_suppl). 1057–1057. 5 indexed citations

Cortés, Javier, P. Fumoleau, Giulia Bianchi, et al.. (2012). Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Journal of Clinical Oncology. 30(14). 1594–1600. 182 indexed citations

Brain, Étienne, Sandrine Baffert, P. Cottu, et al.. (2012). Abstract OT3-3-10: ASTER 70s: Benefit of adjuvant chemotherapy for oestrogen receptor-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) multicentre phase III trial.. Cancer Research. 72(24_Supplement). OT3–3. 1 indexed citations

Kolesnikov-Gauthier, H., Laurence Vanlemmens, Marie‐Christine Baranzelli, et al.. (2011). Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first course. Breast Cancer Research and Treatment. 131(2). 517–525. 38 indexed citations

Soubeyran, Pierre, Carine Bellera, Damien Heitz, et al.. (2011). Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project.. Journal of Clinical Oncology. 29(15_suppl). 9001–9001. 112 indexed citations

10.

Dewas, S., V. Servent, X. Mirabel, et al.. (2010). Results and special considerations when treating elderly patients with CyberKnife®: A review of 345 cases. Critical Reviews in Oncology/Hematology. 79(3). 308–314. 4 indexed citations

11.

Mailliez, Audrey, Capucine Baldini, J. Ton Van, et al.. (2010). Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. British Journal of Cancer. 103(6). 772–775. 42 indexed citations

12.

Rousseau, Frédérique, F. Rétornaz, Florence Joly, et al.. (2010). Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO). Critical Reviews in Oncology/Hematology. 76(1). 71–78. 9 indexed citations

13.

Mailliez, Audrey, Capucine Baldini, V. Servent, et al.. (2010). Nasal septum perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?. Journal of Clinical Oncology. 28(15_suppl). 671–671. 1 indexed citations

14.

Kolesnikov-Gauthier, H., Laurence Vanlemmens, Marie‐Christine Baranzelli, et al.. (2010). Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.. Journal of Clinical Oncology. 28(15_suppl). 563–563. 7 indexed citations

15.

Mailliez, Audrey, et al.. (2010). Abstract P3-14-11: Trastuzumab Cardiac Toxicity and HER2 Polymorphism: A Case-Control Study. Cancer Research. 70(24_Supplement). P3–14. 2 indexed citations

16.

Mallet, Y., et al.. (2009). Head and neck cancer surgery in the elderly – Does age influence the postoperative course?. Oral Oncology. 46(2). 92–95. 46 indexed citations

17.

Cutuli, B., Renaud Fay, B. De Lafontan, et al.. (2004). Carcinome canalaire in situ du sein. La Presse Médicale. 33(2). 83–89. 7 indexed citations

18.

Braud, A.C., F. Joly, María Rios, et al.. (2004). Preservation of Activities Daily Living (ADL) in a phase-II impact study of oral capecitabine and vinorelbine in the treatment of metastatic carcinomas in patients 70 and older: The GERICO-01 Study by the French FNCLCC Group. Journal of Clinical Oncology. 22(14_suppl). 8160–8160. 4 indexed citations

19.

Cutuli, B., B. De Lafontan, H. Mignotte, et al.. (2002). Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience. International Journal of Radiation Oncology*Biology*Physics. 53(4). 868–879. 96 indexed citations

20.

Cutuli, B., B. De Lafontan, H. Mignotte, et al.. (2001). Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. European Journal of Cancer. 37(18). 2365–2372. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact